10-Q: MDB Capital Holdings Reports Q1 2025 Results, Impacted by Investment Losses and Equity Method Accounting

MDB Capital Holdings' Q1 2025 results reveal a net loss driven by unrealized investment losses and the adoption of equity method accounting for eXoZymes after its IPO.

Summary

• MDB Capital Holdings, LLC reported a net loss of $6.6 million for the three months ended March 31, 2025, compared to a net loss of $7.6 million for the same period in 2024.
• The company's operating income was $828,098, a significant increase from the operating loss of $660,389 in the prior year, primarily due to investment banking activity.
• Unrealized losses on investment securities were $1.46 million, compared to $747,268 in the prior year.
• Fee income from the licensed broker-dealer was $2.14 million, compared to none in the prior year.
• General and administrative costs decreased slightly to $6.74 million from $7.01 million.
• Research and development costs decreased to $0 due to the deconsolidation of eXoZymes, compared to $277,582 in the prior year.
• The company recorded an equity in loss of equity method investee of $872,518 related to eXoZymes.
• Loss per Class A common share was $0.66, compared to $0.78 in the prior year.
• As of March 31, 2025, the company had cash and cash equivalents of $19.55 million.
• The company's total assets were $68.63 million, compared to $71.98 million at December 31, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results, with improved operating income offset by net losses and unrealized investment losses. The company also acknowledges a material weakness in internal control over financial reporting, which further dampens the sentiment.

Positives

• Operating income improved significantly due to investment banking activity.
• General and administrative costs decreased slightly.
• Fee income from the broker-dealer was $2.14 million compared to none in the prior year.
• The company has $19.55 million in cash and cash equivalents.

Negatives

• The company reported a net loss of $6.6 million.
• Unrealized losses on investment securities were $1.46 million.
• The company recorded an equity in loss of equity method investee of $872,518 related to eXoZymes.
• The company's total assets decreased from $71.98 million to $68.63 million.

Risks

• The company's business activities are subject to external risks such as inflation, supply chain issues, and potential recession.
• Changes to United States tariff and import/export regulations may have an adverse effect on the company's business, financial condition and results of operations.
• Government action on tariffs and research grants and other funding may impede the company's ability to conduct its research and to raise capital by and for its partner companies and other clients.
• The company acknowledges a material weakness in internal control over financial reporting, though it believes the financial statements fairly present the company's position.

Future Outlook

The company is continuing to monitor economic matters and will adjust its current business and financing plans as more information and guidance become available.

Industry Context

The company operates in the financial services and technology development industries, both of which are subject to significant market and regulatory risks. The performance of the company's broker-dealer segment is tied to the overall health of the capital markets, while the success of its technology development segment depends on the ability to identify and develop commercially viable technologies.

Comparison to Industry Standards

• It is difficult to compare MDB Capital Holdings directly to industry standards due to its unique business model, which combines financial services with technology development.
• However, the company's broker-dealer segment can be compared to other small-cap investment banks and brokerage firms.
• The company's technology development segment can be compared to venture capital firms and early-stage biotech companies.
• The company's Q1 2025 results are mixed, with improved operating income offset by unrealized investment losses and the impact of equity method accounting.
• Further analysis is needed to determine how the company's performance compares to its peers.

Legal Proceedings

• As of March 31, 2025 and 2024, the Company was not subject to any pending or threatened legal claims or actions.

Related Party Transactions

• During the three months ended March 31, 2025 and 2024, the Company paid $ 455,358 and $ 320,792 , respectively, which is inclusive of expenses and fees, for contracted labor, recorded against general and administrative expenses.
• During the three months ended March 31, 2025, PatentVest, a 100 % entity owned the Company, engaged in transactions with eXoZymes and recognized revenues of $ 45,364 .
• During the three months ended March 31, 2025, the Company recorded related party receivables totaling $ 86,764 , this amount is for services performed by PatentVest on behalf of eXoZymes.
• Additionally, the Company recorded accrued expenses of $ 22,176 payable to officers and directors, representing reimbursable expenses incurred in the ordinary course of business.

Stakeholder Impact

• Shareholders: The net loss and unrealized investment losses may negatively impact shareholder value.
• Employees: The company's financial performance may impact employee compensation and job security.
• Customers: The company's ability to provide services to its customers may be affected by its financial condition.
• Suppliers: The company's ability to pay its suppliers may be affected by its financial condition.
• Creditors: The company's ability to repay its debts may be affected by its financial condition.

Next Steps

• The company is implementing measures designed to ensure that control deficiencies contributing to the previously disclosed material weakness are remediated, such that these controls are designed, implemented, and operating effectively.
• The company expects these changes to materially improve its internal controls.

Key Dates

Keywords

MDB Capital Holdings, financial results, Q1 2025, investment losses, equity method, eXoZymes, broker-dealer, PatentVest, MDB Minnesota One, financial statements